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Fragile X-associated tremor/ataxia syndrome (FXTAS) is a rare neurodegenerative
disorder caused by a 55–200 CGG repeat expansion in the 5′ untranslated region of
the Fragile X Mental Retardation 1 (FMR1) gene. FXTAS is characterized by progressive
cerebellar ataxia, Parkinsonism, intention tremors and cognitive decline. The main
neuropathological hallmark of FXTAS is the presence of ubiquitin-positive intranuclear
inclusions in neurons and astrocytes throughout the brain. The molecular pathology
of FXTAS involves the presence of 2 to 8-fold elevated levels of FMR1 mRNA, and
of a repeat-associated non-AUG (RAN) translated polyglycine peptide (FMRpolyG).
Increased levels of FMR1 mRNA containing an expanded CGG repeat can result in
cellular toxicity by an RNA gain-of-function mechanism. The increased levels of CGG
repeat-expanded FMR1 transcripts may create RNA foci that sequester important
cellular proteins, including RNA-binding proteins and FMRpolyG, in intranuclear
inclusions. To date, it is unclear whether the FMRpolyG-positive intranuclear inclusions
are a cause or a consequence of FXTAS disease pathology. In this report we studied the
relation between the presence of neuronal intranuclear inclusions and behavioral deficits
using an inducible mouse model for FXTAS. Neuronal intranuclear inclusions were
observed 4 weeks after dox-induction. After 12 weeks, high numbers of FMRpolyG-
positive intranuclear inclusions could be detected in the hippocampus and striatum, but
no clear signs of behavioral deficits related to these specific brain regions were found. In
conclusion, the observations in our inducible mouse model for FXTAS suggest a lack of
correlation between the presence of intranuclear FMRpolyG-positive aggregates in brain
regions and specific behavioral phenotypes.
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INTRODUCTION
Fragile X-associated tremor/ataxia syndrome (FXTAS) is a late-
onset neurodegenerative disease that is characterized mainly
by essential tremor, cerebellar ataxia, Parkinsonism, peripheral
neuropathy and cognitive decline (Hagerman et al., 2001;
Tassone et al., 2007; Hagerman and Hagerman, 2013, 2016).
FXTAS leads to cerebral and cerebellar atrophy, with increased
T2 signal intensity in MRI images of the middle cerebellar
peduncles as diagnostic hallmark (Brown and Stanfield, 2015).
Carriers of a premutation in the FMR1 gene, consisting of
a 55–200 CGG repeat expansion, are at risk of developing
FXTAS. Such intermediate repeat expansions lead to elevated
levels of FMR1 mRNA (Tassone et al., 2000; Kenneson et al.,
2001; Salcedo-Arellano et al., 2020). In contrast, longer repeat
expansions, more than 200 units, induce silencing of FMR1
mRNA, which results in a lack of FMRP protein, causing the
neurodevelopmental Fragile X syndrome (Bassell and Warren,
2008; Salcedo-Arellano et al., 2020).
Several mechanisms by which the premutation and the
consequential increase in FMR1 mRNA levels may lead to
the development of FXTAS have been proposed. Of these,
arguably the most studied process is the formation of intranuclear
inclusions that has been very well-documented in patients as
well as in animal models and their occurrence has been linked
to alterations at the cellular level in neurons and astrocytes
(Louis et al., 2006; Jin et al., 2007; Berman et al., 2014; Ma
et al., 2019; Haify et al., 2020). The intranuclear inclusions
are mainly composed of proteins and to date more than 200
different proteins have been identified in nuclear inclusions
(Iwahashi et al., 2006; Ma et al., 2019). FMR1 mRNA containing
a CGG repeat expansion, although present itself only in relatively
low concentrations in the nuclear inclusions, could act as a
scaffold binding place for the other components (Cid-Samper
et al., 2018; Langdon et al., 2018; Ma et al., 2019). The putative
pathogenicity of these inclusions could be based on depleting
essential molecules, including RNA-binding proteins (Jin et al.,
2007; Sofola et al., 2007; Qurashi et al., 2011; Sellier et al.,
2013). Another, not necessarily mutually exclusive, potential
pathogenic mechanism is repeat-associated non-AUG (RAN)
translation through which a toxic polyglycine (FMRpolyG)
protein is produced from the elongated FMR1 CGG repeat
mRNA (Todd et al., 2013; Sellier et al., 2017; Krans et al., 2019).
To date, the relative contributions of the RNA-based inclusions
and the expression of toxic FMRpolyG to human pathology are
still matter of debate. It has even been suggested that in early
disease state, the inclusions may serve a protective function
by sequestering FMRpolyG (Greco et al., 2006; Hagerman and
Hagerman, 2016).
Our current clinical, molecular and histopathological
understanding of FXTAS in patients is mostly derived from
studies in mouse models. Several mouse models have been
generated to study the (neuro)pathology and behavioral effects
of FXTAS. Initially two knock-in (KI) mouse models were
generated: the Dutch (CGGdut) and the NIH (CGGnih) KI mouse
model. Both KI mouse models display FXTAS pathology at
the genetic, molecular, histological and behavioral level with
slight differences. Both show ubiquitin-positive intranuclear
inclusions throughout the entire brain, but these inclusions are
more common in the CGGdut KI mice. Behavioral examination
of both CGG KI mice revealed memory impairment (Hunsaker
et al., 2009), increased levels of anxiety in the CGGdut KI mice
while CGGnih KI mice show decreased levels of anxiety. Also,
assessment of motor function in the CGGdut KI mouse model
showed impairment with increasing age of the mice (Van Dam
et al., 2005). This observed cognitive decline and motor function
impairment in these mice may reflect the progressive cognitive
decline and functionality impairment observed in FXTAS
patients. Although both KI mouse models nicely recapitulate
FXTAS disease pathology, the time to generate a phenotype
is a major disadvantage. It takes roughly up to 52–72 weeks
before any phenotype is observed in these mice. Therefore,
several transgenic mouse models were developed to study
specific research questions of FXTAS disease pathology such
as RAN-translation, mRNA containing expanded CGG repeat
and potential therapeutic interventions. We refer the reader
to more advanced and detailed reviews covering all available
mouse models for the premutation and FXTAS (Berman et al.,
2014; Haify et al., 2020). All these mouse models show presence
of ubiquitin-positive and FMRpolyG-positive inclusions in the
central nervous system (CNS) in neurons and astrocytes as
well as in non-CNS organs, thus display the most prominent
neuropathological hallmark in FXTAS disease pathology, with
the notable exception of the intention tremor.
We studied the occurrence of intranuclear inclusions in
a novel inducible mouse model for FXTAS, and related
these to quantitative alterations in mouse behavior. To avoid
interactions during development, we induced—in adult mice—
the expression of a randomly integrated 103× CGG repeat
expansion in the mouse under control of the neuron-
specific Ca2+/calmodulin-dependent protein kinase II alpha
(CamKII-α) promoter. The CamKII-α driver induces expression
throughout the entire forebrain, but also in several other
regions in the cerebrum such as the hippocampus and the
basal ganglia, which are regions known to be involved in
FXTAS disease pathology (Greco et al., 2002; Wang et al.,
2013). In this report we mainly focused on the dentate
gyrus (DG) and CA3 region of the hippocampus, and the
striatum, being part of the basal ganglia. These regions are
believed to contribute to several behavioral impairments in
FXTAS such as in motor learning and coordination, and
memory (Scaglione et al., 2008; Hagerman and Hagerman,
2013; Haify et al., 2020). Also, cognitive decline based on
performance in spatial learning, memory tasks, executive
motor function impairments and anxiety associated disorders
are observed in premutation carriers and FXTAS patients
(Hasegawa et al., 2009). For a period of 3 months after
induction, we quantified the formation of inclusions in the
brain and characterized the behavioral performance. As expected,
and in line with the expression pattern of the CamKII-
α promoter (Burgin et al., 1990), we found intranuclear
inclusions in the hippocampus and the striatum, already
appearing 4 weeks after dox-induction. To our surprise,
however, virtually no impact on behavioral performance
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was detectable even after 3 months of dox-induction. We
therefore propose based on this study that intranuclear
inclusions do not have an immediate detrimental effect
on neuronal function and this may point to a protective




For this study, male and female CamKII-α-rtTA/TRE-103CGG-
GFP-mice with a C57BL6/J background were used (Figure 1A).
This CamKII-α inducible mouse model was generated similarly
to the ubiquitous inducible mouse model by random integration
of the transgenes in the genome (Hukema et al., 2014). The
TRE-103CGG-GFP mice were crossed with the CamKII-α-rtTA
driver line to generate double transgenic mice using the Tet-On
system. Dox-treatment was initiated at the age of 9 weeks in these
mice. Dox drinking water contained 2 mg/ml doxycycline hyclate
(Sigma) in 5% sucrose (Sigma) and was refreshed every 2–3 days.
Genotyping
For genotyping, toe clips from P5–7 mice and, after sacrificing,
lung tissue, were incubated overnight in 300 µl tail digestion
buffer [TDB; 50 mM KCl, 10 mM Tris-HCl pH 9, 0.1%
Triton X-100 and 0.15 µg proteinase K (Roche)] at 55◦C. The
following day, samples were heat inactivated for 5′ at 95◦C
and centrifuged to remove debris. Next, 1 µl of supernatant
was used as template DNA in PCR. Templates were checked
for presence of rtTA and/or TRE. The following PCR mix
was used: 10× FastStart DNA Polymerase buffer with MgCl2
(Roche), 25 mM dNTPs, primers (10 mM), FastStart DNA
polymerase (5 U/µl; Roche) and sterilized water. The PCR
program consisted of 4′ denaturation at 94◦C, followed by 30
cycles of amplification through 30′′ at 94◦C, 30′ at 60◦C, and 90′′
at 72◦C, and ended with 5′ at 72◦C. PCR products were visualized
by adding 10 µl 3× loading mix [30% Orange G (Sigma),
0.2% GelRed (Biotium) in H2O] to 5 µl of PCR product and
separating using gel electrophoresis on a 1.5% agarose gel. Gels
were scanned using Gel Doc XR+ (Bio-Rad) Molecular Imager
with Image Lab software. The TRE transgene was amplified
using forward primer 5′-GCTTAGATCTCTCGAGTTTAC-3′
and reverse primer 5′-ATGGAGGTCAAAACAGCGTG-3′. The
rtTA transgene was amplified using forward primer 5′-
CAGCAGGCAGCATATCAAGGT-3′ and reverse primer 5′-
GCCGTGGGCCACTTTACAC-3′.
Repeat Length PCR
Repeat length was determined according to an in-house PCR
protocol. Brain tissue from mice having 11CGGs (positive
control), wildtype mice (negative control) and TRE-103CGG-
GFP 4 weeks old mice were incubated overnight in 300 µl tail
mix buffer [50 mM Tris pH = 7.5, 10 mM EDTA, 150 mM
NaCl, 1% SDS and 20 µl proteinase K (10 mg/ml; Roche Cat.
#3115852)] at 55◦C. The next day, 100 µl 6 M NaCl was added
to the samples and samples were shaken very well to induce
FIGURE 1 | Schematic representation of the Tet-On system and behavioral
testing of a new brain-specific mouse model for FXTAS. (A) Brain-specific
expression of the expanded CGG repeat RNA coupled to GFP was studied in
the CamKII-α-rtTA/TRE-103CGG-GFP inducible mouse model with a
C57BL6/J background. The Tet-On system was used to generate double
transgenic mice expressing the expanded CGG repeat at the RNA level.
Expression of the reverse tetracycline transactivator (rtTA) is controlled by the
CamKII-α promoter on a separate transgene. Upon dox administration, rtTA
will be activated and can bind the tet response element (TRE) on another
transgene, which induces expression of the expanded CGG repeat at the RNA
level and GFP at the protein level. As the transgene contains the 5’-UTR of the
FMR1 gene with an expanded CGG repeat, the FMRpolyG polypeptide is
produced from the expanded CGG repeat by RAN translation. (B) Schematic
overview of the experimental schedule for histological analysis and behavioral
testing. At around 9 weeks of age, dox-treatment started. Around 10 weeks
later, ErasmusLadder tests were performed, followed by balance beam and
grip tests. Finally, the mice were subjected to the Morris water maze test.
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precipitation of cell debris. Samples were centrifuged (10,000 g
at RT for 10 min) to remove cell debris. The supernatant was
transferred to a new tube and 1 ml 100% EtOH was added (shake
very well). Tubes were centrifuged at 10,000 g for 10 min to form
DNA pellet. Next, the supernatant was discarded and DNA pellet
was washed with 500 µl 70% EtOH. Samples were centrifuged at
10,000 g for 5–10 min. The supernatant with EtOH was discarded
and the DNA pellet was left to dry to the air for a couple of
minutes. The DNA pellet was resuspended in 100 µl sterilized
water. Next, 1 µl of supernatant was used as template DNA
in the PCR reaction mix (total volume 21 µl). Following PCR
mix was used: 10 µl Betaine (5 M), 4 µl 5× expand HF buffer
without Mg2+, 1.5 µl MgCl2 (25 mM) 1 µl forward primer (10
µM), 1 µl reverse primer (10 µM), 0.2 µl dNTP mix (100 mM)
(25 mM each), 0.2 µl FastStart Taq DNA polymerase (5 U/µl;
Roche) and 2.1 µl sterilized water. The PCR program consisted of
10’ denaturation at 98◦C, followed by 35 cycles of amplification
through 35 s at 98◦C, 35 s at 58◦C and 3 min at 72◦C, and
ended with a cooling step at 15◦C. For quantification of the
DNA size, 1 µl 1 Kb Plus DNA ladder (Thermo Fisher Scientific;
Cat. # 10787018) was used with and without 0.2% GelRed
(Biotium) in dH2O. Staining with GelRed after electrophoresis
run is necessary because GelRed interferes with the DNA and
therefore influences CGG repeat measurement. To front track
DNA separation during gel electrophoresis, 10 µl 30% Orange
G (Sigma) loading dye was added to 5 µl of PCR product on
the 1.5% agarose gel. After gel electrophoresis run, the agarose
gel was stained for 30 min in 500 ml 1X TBE-buffer (1L 5X
TBE-buffer: 54 g Tris (CAS #77-86-1), 27.5 g boric acid (CAS
#10043-35-3) and 20 ml 0.5 M EDTA pH = 8.0 (CAS #60-00-
4) + 50 µl 0.2% GelRed (Biotium). Gels were scanned using Gel
Doc XR+ (Bio-Rad) Molecular Imager with Image Lab software.
The CGG repeat was amplified using the following forward
primer 5’-ATCCACGCTGTTTTGACCTC-3’ and reverse primer
5’-CCAGTGCCTCACGACCAAC-3’.
RNA Isolation and cDNA Synthesis
RNA isolation was performed on dox and sucrose treated
16 weeks old CamKII-α-rtTA/TRE-103CGG-GFP mice. Per
treatment group n = 3 brains were used for RNA isolation. Prior
to lysing, samples were thawed on ice and supplied with RIPA-
buffer containing 0.05% protease inhibitors (Roche), 0.3% 1 M
DTT (Invitrogen) and 40U RNase Out (Roche). Samples were
mechanically lysed, followed by 30 min of incubation on ice.
After 30 min of incubation, mechanical lysing was repeated to
ensure total homogenization. Homogenate was added to RNA
Bee (Tel-Test) in a 1:10 (v/v) ratio and mixed thoroughly.
Chloroform (Millipore) was added to mixture in a 1:5 ratio
(v/v), mixed thoroughly and incubated on ice for 15 min. After
incubation the mixture was centrifuged for 15 min at 4◦C and
supernatant was collected and supplied with 0.6× (v/v) 100%
2-propanol (Honeywell). After 15 min centrifugation at 4◦C,
supernatant was discarded. Remaining pellet was washed with
80% EtOH (Honeywell) in duplicate with brief centrifugation at
4◦C between washes. Following removal of residual supernatant,
50 µl dH2O was added and concentration was determined using
the NanoDrop 2000 (Thermo Fisher Scientific).
Quantitative Real-Time PCR
Reverse transcriptase (RT) was performed using 1 µg of RNA
with the iScript cDNA synthesis kit (Biorad) according to
manufacturer’s instructions. RNA was treated with DNase before
cDNA synthesis. Q-PCR using iTaq Supermix (BioRad) was
performed on 0.1 µl RT product. Cycling conditions were an
initial denaturation of 3 min at 95◦C, followed by 35 cycles of
each 5 s at 95◦C and 30 s at 60◦C. As a reference gene GAPDH
was used. For statistical analysis the two-sample unpaired t-test
assuming equal variance was used.
Immunohistochemical Staining
Tissues were fixed overnight in 4% paraformaldehyde (PFA) at
4◦C and embedded in paraffin according to in-house protocols.
Sections of 6 µm were cut and placed on silane coated slides
(Klinipath). The sections were deparaffinized in decreasing
concentrations of alcohol—starting with xylene and ending in
demineralized H2O—before performing antigen retrieval by
microwave treatment in 0.01 M sodium citrate (pH = 6).
Endogenous peroxidase activity was blocked with 0.6% H2O2
in PBS. When staining for FMRpolyG an additional incubation
with proteinase K (5 µg/ml) was performed for 20–30 min
at 37◦C to ensure optimal antibody binding. Staining was
performed overnight at 4◦C with primary antibodies diluted in
PBS/0.5% milk/0.15% glycine (PBS+). Staining with secondary
antibodies was performed at RT for 60 min. Antigen-antibody
complexed were visualized using DAB-substrate (DAKO), after
which slides were counterstained with hematoxylin for 5 min
and subsequently mounted with Entellan (Merck Milipore
International). Antibodies used are listed in Table 1 hereafter.
Behavioral Testing
Muscle function was tested using a hanging wire test. A metal
wire with a diameter of 2 mm was suspended around 20 cm
above a cage. The mouse was brought to the wire so that he could
grasp the wire with his front paws after which the latency to fall
was recorded. The maximal trial duration was 60 s. In addition,
we used the Bioseb grip strength test (Bioseb, Vitrolles, France).
For this test, the mouse was placed on a metal grid and after he
clamped to the grid with all four limbs, he was gently pulled down
by the base of his tail. The maximal force was measured and the
average of three consecutive trials was calculated.
The fine motor coordination of the mice was tested on
the balance beam. During 2 consecutive days, the mice were
habituated to the setup that consisted of a horizontal wooden
beam with a diameter of 12 mm and a length of 100 cm located
TABLE 1 | Antibodies.
Target Dilution Host Source Catalog No.




GFP 1:2000 Mouse Roche 11814460 001
Mouse specific anti-GFP and anti-FMRpolyG (8FM) antibodies were used to
visualize GFP expression and the FMRpolyG protein aggregates in mouse brain,
respectively.
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approximately 50 cm above a table. Each mouse was placed on
one side of the beam and walked over the beam to a home cage at
the other side of the beam. After two trials, the beam was replaced
by one with a diameter of 8 mm and also on this beam two trials
were performed. On the third day, the performance of the mice
was quantified by counting the number foot slips and falls. Each
mouse crossed each beam twice and the average time required to
reach the other side of the beam was measured, taking only trials
without falls into account.
Locomotor patterns were recorded on a horizontal
ladder flanked by two plexiglass walls spaced 2 cm apart
(ErasmusLadder, Noldus, Wageningen, Netherlands) as
described previously (Vinueza Veloz et al., 2015). The ladder
consisted of two rows of 37 rungs placed in an alternated
high/low pattern. The rungs were spaced 15 mm apart and the
height difference between high and low rungs was 9 mm. Each
rung was connected to a pressure sensor recording rung touch.
During a trial, the mouse had to walk from a shelter box on one
side of the ladder to another on the other end. Trial start was
indicated by lighting an LED in the shelter box followed 3 s later
by a strong tail wind. Early escapes, thus before the LED was
switched on, were discouraged as they triggered a strong head
wind. In between trials, there was a resting period. Mice were
first habituated to the setup by letting them freely explore the
ladder for 15 min during which no light or air cues were given.
On the next day, training started with 44 trials on each day. The
initial training consisted of six daily sessions, after which the
mice were measured once a week. Sensor touches were filtered to
delete single backsteps or fake hind limb steps using the factory
settings. For the further analysis, we used the touches of the front
limbs with the first and the last step of each trial being deleted.
Using the water maze test, we quantified the spatial memory of
the mice. Each mouse was placed on the border of a circular pool
with a diameter of 120 cm filled with a mixture of water and non-
toxic white paint kept constant at 26◦C. In the pool, a platform
with a diameter of 11 cm diameter was hidden 1 cm below the
water surface. The time to find the platform was recorded on
two trials each day on 5 consecutive days. When the mouse did
not find the platform within 60 s, the trial was stopped. On days
6 and 7, a probe trial was given. During the probe trials, the
platform was absent and the mice were allowed to swim for 60
s while their trajectory was tracked (EthoVision XT11, Noldus,
Wageningen, Netherlands). The data of the probe trials were
analyzed by subdividing the pool in four quadrants, with the
original position of the platform in the middle of quadrant 3.
We marked the original platform position as well as the same
shape at the corresponding position in the other three quadrants
and counted how often the mouse passed the borders of each of
these positions per trial. We considered a crossing if it involved
more than 50% of the body of the mouse. On top of that, we also
quantified the time spent in each quadrant.
The battery of behavioral tests is schematically represented in
time in Figure 1B.
Statistics
Behavioral performance on each paradigm was compared
between mice treated with and without doxycycline. The
statistical tests used are mentioned in the Results section, whereby
we used non-parametric tests for data that were not normally
distributed. Throughout the manuscript, we considered a p-value
of 0.05 or less as indication for statistical significance.
RESULTS
Expanded CGG Expression Results in
Inclusion Formation in the Hippocampus
and Basal Ganglia
First of all, we studied the expression pattern of the FMRpolyG-
GFP fusion protein in CamKII-α-rtTA/TRE-103CGG-GFP mice
after induction of transgene expression by the addition of
doxycycline (dox) to the drinking water. First, repeat length
in the transgene was verified using an in-house PCR protocol.
Repeat length PCR shows the repeat size of 103× CGGs at
approximately 480 bp compared to the control 11 CGGs length
at 290 bp (Supplementary Figure S1A). To verify whether dox
treatment did not affect murine Fmr1 mRNA expression, we
performed quantitative real-time PCR on brain tissue of treated
and control mice. The data show that dox treatment had no
effect on Fmr1 mRNA expression in the brain as tested in the
hippocampus (Supplementary Figure S1B). Since the transgene
expression was under the CamKII-α promoter, we expected the
FMRpolyG protein to be present in neurons of, among other
regions, the hippocampus, the neocortex, the basal ganglia, and
in the posterior part of the cerebellum, more specifically lobule X
(Hasegawa et al., 2009; Wang et al., 2013). In our hands, already
after 4 weeks of dox treatment, GFP expression, indicative of
FMRpolyG expression, was found in all aforementioned brain
regions. After 12 weeks of dox treatment, the expanded CGG
repeat was strongly expressed in the striatum of the basal
ganglia, the hippocampus, the neocortex, and lobule X of the
cerebellum (Figures 2A,B,D,E). Low to modest expression of
GFP was present at 12 weeks in the hypothalamus, the colliculus
inferior and superior (Figures 2C,D), and other sub-regions
of the midbrain.
Next, we investigated whether FMRpolyG expression was
associated with the formation of nuclear inclusions in the
CamKII-α-rtTA/TRE-103CGG-GFP mice. To this end, we
compared brain sections stained for FMRpolyG from mice that
did receive dox with those from mice that did not. As expected,
we could not detect any inclusions in the control mice. However,
the mice treated with dox developed spherical FMRpolyG-
positive inclusions in most of the brain regions in which GFP
expression was observed. The highest density of inclusions was
found in the striatum, the CA3 region of the hippocampus and
the hypothalamus (Figures 3B–D). Lower densities were present
in the DG region of the hippocampus, as well as in the inferior
and the superior colliculus (Figures 3A,E). We did not observe a
perfect correlation between GFP expression and the occurrence
of inclusions: in lobule X of the cerebellum, no inclusions were
found despite the presence of GFP (Figures 2E,F). In general,
during 12 weeks of dox treatment, the number of inclusions
increased over time with regional differences. Quantification
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FIGURE 2 | GFP expression in multiple brain regions. GFP expression (brown staining) was visualized using immunohistochemical staining with a mouse specific
anti-GFP antibody in sagittal brain sections at 12 weeks after onset of dox-treatment. Strong expression of GFP was present in the striatum (A), the hippocampus
(B), the hypothalamus (C), and the cerebral cortex (D). Lower levels of expression were present in the superior and inferior colliculus (D). In the cerebellum, GFP
expression was only observed in vermal lobule X (E, indicated area amplified in F). 3V, third ventricle; cc, corpus callosum, Ctx, cerebral cortex; DG, dentate gyrus; f,
fornix; Hy, hypothalamus; IC, inferior colliculus; SC, superior colliculus; Str, striatum; Th, thalamus; TRS, triangular nucleus of the septum.
FIGURE 3 | FMRpolyG-positive inclusions are predominantly located in the nucleus. FMRpolyG-positive inclusions, visible as black dots, were stained using the
mouse anti-FMRpolyG (8FM) antibody. Most often, the FMRpolyG-positive inclusions were observed in the nuclei (black arrows) but occasionally also outside the
nuclei (red arrows). FMRpolyG-positive inclusions were found in the dentate gyrus (DG, A) and the CA3 region of the hippocampus (B), the striatum (C), the
hypothalamus (D), and in the colliculi (E). Rectangles indicate areas enlarged in insets. Scale bars = 50 µm. (F) The prevalence of FMRpolyG-positive inclusions
increased over time after onset of dox treatment. Bars indicated average values and error bars the sd.
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of FMRpolyG-positive inclusions (Figure 3F) was only done
in the hippocampus and the striatum of the basal ganglia,
since these regions are known to be involved in FXTAS disease
pathology (Greco et al., 2002). Irrespective of the brain region
involved, most inclusions were located intranuclearly. Sometimes
two or more smaller inclusions were located in the same
nucleus. In summary, dox induced the production of CGG
RNA in CamKII-α-rtTA/TRE-103CGG-GFP mice in several
brain regions, which resulted in the formation of FMRpolyG-
positive nuclear inclusions, predominantly in the striatum and
the hippocampal CA3 region.
Absence of Behavioral Phenotype in
Mice Expressing FMRpolyG-Positive
Inclusions
To test whether the expression of the CGG repeat and the
resulting nuclear inclusions had any impact on mouse behavior,
we subjected the mice to a battery of behavioral tests. To control
for possible confounding problems with the general condition of
the mice, we first tested the muscle strength using the hanging
wire and the Bioseb grip strength tests 12 weeks after the start
of the dox treatment. The latency to fall was 22.0 ± 11.0 vs.
26.5 ± 10.2 s (control vs. dox mice, averages ± s.d., p = 0.385,
t = 0.944, df = 17, t-test Figure 4A) during the hanging wire
test and the force was 1.79 ± 0.37 vs. 1.53 ± 0.39 N (control vs.
dox mice, averages ± s.d., p = 0.336, t = 0.991, df = 17, t-test
Figure 4B) during the Bioseb grip strength test. We therefore
conclude that there were no indications for changes in muscle
strength due to the dox treatment.
Next, we tested the overall motor control and balance on the
balance beam after 12 weeks of dox treatment. The numbers of
hind foot slips per trial were comparable between control and
dox mice [thick beam: 2.0 (inter-quartile range (IQR): 1.5) vs. 1.5
(IQR: 0.9), p = 0.876, U = 47.5; thin beam: 1.0 (IQR: 1.4) vs. 2.5
(IQR: 2.5), p = 0.220, U = 33.5, medians, Mann-Whitney tests,
Figure 4C]. Also the time required to cross the beam were not
really different between control and dox mice [thick beam: 8.3
(IQR: 2.5) vs. 7.0 (IQR: 1.9) s, p = 0.593, U = 42.5; thin beam:
9.8 (IQR: 8.6) vs. 12.5 (IQR: 9.1), p = 0.820, U = 46.5, medians,
Mann-Whitney tests, Figure 4C]. We take this as a sign that the
treatment did not impair the overall motor control and ability
to keep balance.
We continued by describing the behavior on the
ErasmusLadder, which is a horizontal ladder consisting of
two rows of rungs in an alternating high/low pattern spanning
the space between two shelter boxes. After habituation and
initial training, we measured the performance at 10, 11, and 12
weeks after the start of dox treatment. The start of each trial was
indicated by switching on an LED in the start box and this was
followed by a strong tail wind 3 s later. In roughly 75% of the
trials, the mice waited until the tail wind started before leaving
the start box. Leaving upon perception of the visual cue or even
before that was observed less often. Changes in this pattern could
be a sign of cognitive impairment (Vinueza Veloz et al., 2012),
but these were not observed between control and dox mice
(p = 0.516, 3× 2 Fisher’s exact test, Figure 4D).
Next, we characterized the stepping pattern on the
ErasmusLadder. Wild type C57BL/6J mice have a tendency
to avoid the lower rungs and typically make steps from one
high rung to the next or the second next high rung (Vinueza
Veloz et al., 2015). We considered these small and regular steps,
respectively. Long steps, skipping at least two higher rungs, and
lower rung steps occurred much less often, as did other irregular
steps such as backwards walking. Thus, also regarding the
stepping pattern, no impact of the dox treatment was observed
(Table 2 and Figures 4E–G).
Finally, to test for putative defects in spatial memory
formation, we subjected the mice to the Morris water maze test
around 12 weeks after the start of the dox treatment. During
5 consecutive days, the mice were trained to find a hidden
platform just below the surface of an opaque, circular pool.
Over the sessions, both control and dox-treated mice managed
to be faster in finding the hidden platform, with no statistically
significant differences between the two groups [p = 0.134, F(1,
17) = 2.479, repeated measures ANOVA, Figure 4H]. On the
next 2 days, the experiment was repeated—but without a hidden
platform. On these probe trials we made video recordings of
the mice (Figure 4I). First, we counted how often the mice
crossed the location where the hidden platform had been during
the training sessions and compared these with crosses of the
analogous locations in the other three quadrants. During the first
probe trial, both control and dox treated mice had a preference
for the real location (in quadrant 3) over the other areas (control:
2.2± 1.5 crosses per trial of the real location vs. 1.0± 0.9 crosses
of the other locations, p = 0.021, U = 60.5, Mann-Whitney test,
dox mice 2.0± 2.2 vs. 0.6± 0.7 crosses, averaged± ss, p = 0.107,
U = 101.5, Mann-Whitney test, control vs. dox mice: p = 0.813,
χ2 = 0.95, χ2 test). During the second probe trial, the preference
of the control mice for the real location was gone (1.8 ± 1.2 vs.
1.6 ± 1.3 crosses, p = 0.624, U = 108.0, Mann-Whitney test), but
remained present in the dox treated mice (3.3 ± 2.3 vs. 1.1 ± 1.1
crosses per trial, p = 0.005, U = 63.0, Mann-Whitney test). This
difference between control and dox mice was on the border of
statistical significance (p = 0.061, χ2 = 7.36, χ2-test, Figure 4J).
This might indicate that the dox-treated mice had more trouble
understanding that the hidden platform was no longer in place.
This, however, was not reflected in the relative dwell times per
quadrant [p = 1.00, F(1, 17) = 0.000, repeated measures ANOVA,
Figure 4K], which leads us to conclude that also the Morris water
maze did not reveal convincing differences in behavior due to
activation of the premutation.
DISCUSSION
Wide-spread occurrence of nuclear inclusions is a major hallmark
of FXTAS. To date, it is a matter of debate whether these
inclusions contribute to cellular pathology in FXTAS, or—in
contrast—slow down the disease process by sequestering toxic
RNA and proteins. Such a protective function has been suggested
for FXTAS (Greco et al., 2006; Hagerman and Hagerman,
2016), but also for other protein-aggregation disorders, such
as Huntington’s disease and SCA1 (Klement et al., 1998;
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FIGURE 4 | Absence of a clear behavioral phenotype in dox-treated mice. Neither the hanging wire test (A) nor the Bioseb grip strength test (B) demonstrated an
impact of dox-treatment on muscle strength. (C) Also, the balance beam test failed to find consistent differences in either the number of slips (left) or the time to
cross (right). The tests were performed on a thick (12 mm diameter) and a thin (8 mm diameter) wooden beam. (D) On the ErasmusLadder, trial starts were indicated
by lighting an LED in the start box, followed 3 s later by a strong tail wind. The fraction of trials with starts before the visual cue (“Early”), during the visual cue (“Light”)
or after the start of the tail wind (“Air”) were comparable between control and dox-treated mice. Data recorded at 10, 11, and 12 weeks after the start of
dox-treatment. (E) The ErasmusLadder consists of alternating high and low rungs. The fractions of short steps (from one high rung to the next), regular steps (from
one high rung to the second high rung), long steps (from on high rung to another, skipping at least two) and lower rung touches were also similar for both groups, as
further illustrated for the fraction of regular steps and lower rung touches (F) as well as for step times (G). The data in (F,G) show the medians with the shades
indicating the inter-quartile range. See Table 2 for a more extensive statistical analysis of the ErasmusLadder test. (H) In the water maze, the mice had to find a
platform hidden just below the water surface. As the water was made opaque, the mice could not see the platform. During 5 consecutive training days, the latency
to find the platform decreased both in control and dox-treated mice. (I) On the next 2 days, the hidden platform was removed (probe trials) and the trajectories of the
mice were recorded. The heat maps indicate the time spent per area of two exemplary mice. The original location of the hidden platform is indicated by a pink
dashed circle in quadrant 3. (J) On the first probe day, the mice crossed the location where the hidden platform had been more often than the analogous regions of
the other quadrants. On the second day, the control mice no longer searched more often in the area where the hidden platform had been (p = 0.624, Mann-Whitney
test), while the dox-treated mice kept searching specifically around the location where the hidden platform had been (p = 0.005, Mann-Whitney test). (K) This
retention, however, was not noticeable when comparing the times spent per quadrant. Unless indicated otherwise, behavioral tests were performed during the 12th
week of dox-treatment. Group sizes were 10 mice.
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TABLE 2 | Step size statistics for the ErasmusLadder.
Treatment Median IQR p F df Test
Step lengths (%)
Short steps (step size = 2) -Dox 6.4 15.8 0.687 0.168 1 Repeated measures ANOVA
+Dox 7.1 22.8
Regular steps (step size = 4) -Dox 76.1 14.2 0.699 0.154 1 Repeated measures ANOVA
+Dox 77.2 22.0
Long steps (step size ≥ 6) -Dox 3.4 7.9 0.688 0.166 1 Repeated measures ANOVA
+Dox 5.1 4.1
Lower rung steps -Dox 1.7 0.9 0.153 2.226 1 Repeated measures ANOVA
+Dox 2.3 0.8
Backsteps -Dox 1.3 1.0 0.629 0.241 1 Repeated measures ANOVA
+Dox 2.1 1.8
Step times (ms)
Short steps (step size = 2) -Dox 303 82 0.751 0.104 1 Repeated measures ANOVA
+Dox 346 101
Regular steps (step size = 4) -Dox 251 59 0.588 0.304 1 Repeated measures ANOVA
+Dox 261 75
The percentages of steps to higher rungs, being either short, regular or long, as well as those to lower steps (irrespective of stride length), and backward steps were
compared at 10, 11, and 12 weeks after onset of dox treatment. Note that the percentages do not add to 100% as some irregular types of steps were not considered here
(in particular, steps starting from lower rungs). Of the two most frequent step categories, also the step times are indicated and compared. The values were first calculated
per mouse, and then compared between the two groups (n = 10 mice/group). The median and interquartile range (IQR) values in this table refer to the recording session
at 12 weeks after onset of dox treatment. All values refer to front paw movements. p-values reflect the between-subject comparisons of repeated measures ANOVAs.
Since not a single p-value was close to the threshold for significance, no correction for multiple comparisons was applied.
Saudou et al., 1998; Cummings et al., 1999; Arrasate et al., 2004).
To study the relation between the development of intranuclear
inclusions and behavioral deficits, we used a novel, inducible and
neuron-specific mouse model for FXTAS under the control of
the CamKII-α promoter. Expression of an expanded 103CGG
repeat RNA transgene is induced by dox and is under the
control of the Tet-On system. This inducible mouse model
shows no evidence of expression in the absence of dox (i.e.,
no leakage of expression), and was induced after completion of
normal development to avoid interaction with developmental
processes. Within a month after transgene induction, FMRpolyG-
positive nuclear inclusions were found in the striatum and
the CA3 region of the hippocampus. Two months after the
occurrence of the first nuclear inclusions, the inclusions were
abundant in most brain areas in which the CamKII-α promoter
is active such as the hippocampus, neocortex and the striatum.
Yet, we could not identify a robust behavioral phenotype that
could be caused by the inclusion pathology in these mice.
Several mouse models have significantly contributed to our
understanding of the molecular mechanisms underlying FXTAS
and have characterized disease progression. Previously, we found
in a different inducible mouse model for FXTAS, using the
heterogeneous nuclear ribonucleoproteins (hnRNP) promoter, a
rapid death after dox-induction. The neuronal level of transgene
expression in these mice was low, and nuclear inclusions were
sparse or even absent in the brain (Hukema et al., 2014). In
contrast, in a third mouse line, under control of the brain-
specific protease-resistant-protein (PrP) promoter, we observed
both the formation of nuclear inclusions and behavioral deficits
(Hukema et al., 2015). These mice developed only a deficit
in the compensatory eye movement pathway after 20 weeks
of treatment with dox. Although expression of the transgene
containing the expanded CGG repeat mRNA was found in the
hippocampus, lobule X of the cerebellum and the striatum, these
expression levels were low with the exception of lobule X of the
cerebellum where expression was the most profound. Together,
these results lead us to question whether the development of
nuclear inclusions is indeed the cause of developing FXTAS
symptoms. Therefore, we developed a new inducible transgenic
mouse model under the control of the CamKII-α promoter
expecting stronger expression in the brain.
In our CamKII-α-rtTA/TRE-103CGG-GFP mouse model,
the expression of GFP followed that of the previously
described distribution of the CamKII-α promoter (Wang et al.,
2013). Immunohistochemical staining shows the strongest GFP
expression in the striatum, the CA3 region of the hippocampus
and lobule X of the cerebellum. Moderate GFP expression was
found in the neocortex, the dentate gyrus, the hypothalamus
and several midbrain areas. In all of these regions, with the
notable exception of the cerebellum, also nuclear inclusions were
formed. If nuclear inclusions in these areas would result in
functional deficits, a broad range of behavioral impairments is
to be expected. As a consequence, typical cerebellar symptoms,
although prominent in FXTAS patients (Hagerman et al., 2001;
Tassone et al., 2007; Hagerman and Hagerman, 2013, 2016), were
not expected in our mouse model since the CamKII-α is only
expressed in a very limited part of the cerebellum. We therefore
focused on spatial learning, that has previously been shown to
be affected in a knock-in mouse model (“the Dutch mouse”)
(Van Dam et al., 2005; Hunsaker et al., 2009), and striatal motor
coordination functions, as they also occur as parkinsonism in
patients (Hagerman et al., 2001).
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An intact hippocampus is essential for normal spatial learning
in the water maze (D’Hooge and De Deyn, 2001; Okada and
Okaichi, 2009; Laeremans et al., 2015). Our mice showed no, or
only marginal, deficits at the water maze test, arguing against a
severely impaired hippocampal function. The striatum is vital for
motor control and striatal damage leads to impaired behavior on
the balance beam (Shear et al., 1998; Feng et al., 2014), which
was not observed in our mice. This lack of an effect on motor
coordination was further substantiated by equal performance of
treated and control mice on the ErasmusLadder and the grip tests.
Although we cannot exclude that there were subtle behavioral
deficits that we did not observe, it is safe to state that there
were no major changes in behavioral performance in spite of the
abundance of nuclear inclusion in the dox treated mice.
The expanded CGG RNA and proteins can aggregate with
many other molecules into nuclear inclusions (Ma et al.,
2019). The expanded CGG RNA on itself is not enough to
induce toxicity and that the production of an out-of-frame
FMRpolyG protein due to RAN translation is necessary for
cellular toxicity (Galloway and Nelson, 2009; Hashem et al.,
2009; Sellier et al., 2017; Derbis et al., 2018). Our present results
indicate that the development of FMRpolyG-positive nuclear
inclusions themselves are probably not very detrimental to the
function of neurons. It remains to be seen whether aggregation
is an active process, aimed at sequestering toxic molecules and
thereby slowing down the disease progression, or more an
epiphenomenon that is a physical consequence of the molecular
structure of the expanded CGG RNA and/or RAN translation
protein FMRpolyG.
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Supplementary Figure 1 | CGG repeat length verification and Fmr1 mRNA
expression in dox-induced transgenic mice. (A) Gel electrophoresis analysis
shows that the CGG repeat length in the CamKII-α-rtTA/TRE-103CGG-GFP
transgenic mice is in the premutation range. Repeat length PCR shows the repeat
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respectively. +L = Ladder with GelRed; -L = Ladder without GelRed;
MUT = TRE-103CGG-GFP (mouse ID: 20464-1); 11CGG = normal repeat length
(positive control); WT = wildtype (negative control); H2O = water control. (B)
Quantification of Fmr1 mRNA expression in the hippocampus of dox-induced
(n = 3) and control (sucrose; n = 2) mice 16 weeks after start of the dox treatment.
Dox-induction does not affect Fmr1 mRNA expression levels in these transgenic
mice. Measurements were repeated twice with the same conditions using
q-RT-PCR and normalized to the average level found in the control-dox mice.
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